Lilly’s Taltz plus Zepbound highlights superior efficacy for adults with psoriatic arthritis and obesity
Posted on March 30, 2026
Eli Lilly has recently announced their new detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one additional weight-related comorbid condition.
Note that at the primary endpoint of 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz monotherapy. A greater reduction in PsA disease activity was seen as early as Week 4 in the Taltz and Zepbound treatment arm (as compared to Taltz alone), before clinically meaningful weight loss was observed. Treatment with Taltz and Zepbound also led to a significant increase in patients achieving Minimal Disease Activity, a high bar for PsA treatment success, along with improvements in fatigue, physical function, mental health-related quality of life, cardiometabolic health and inflammation.
“In TOGETHER-PsA, treating PsA and obesity concurrently with Taltz and Zepbound yielded meaningful, broad improvements in PsA disease activity, inflammation, and outcomes that can impact patients’ daily lives, such as fatigue, disability and quality of life,” said Philip Mease, M.D., Director of Rheumatology Research, Swedish Medical Center and Clinical Professor at the University of Washington, Seattle and TOGETHER-PsA study author. “These two chronic inflammatory diseases are often intertwined, with patients managing a substantial disease burden that remains difficult to treat. This clinical evidence supports a potential transformation in how we approach treatment for this patient population.”
TOGETHER-PsA 36-Week Results
| Taltz | Taltz + Zepbound | |
| Primary Endpoint | ||
| Percentage of patients achieving ACR50 + ≥10% weight reduction | 0.8 % | 31.7 % |
| Key Secondary Endpoints | ||
| Percentage of patients achieving ACR50 | 20.4 % | 33.5 % |
| Percentage of patients achieving ACR20 + ≥5% weight reduction | 10.3 % | 69.7 % |
| Percentage of patients achieving ≥10% weight reduction | 4.5 % | 84.5 % |
| Select Additional Secondary Endpoints and Patient Reported Outcomes | ||
| Percentage of patients achieving Minimal Disease Activity (MDA) | 15.3 % | 26.3 % |
| hsCRP change from baseline, mg/L | −0.44 | −1.79 |
| HAQ-DI total score change from baseline | −0.3 | −0.5 |
| FACIT-Fatigue change from baseline | 4.8 | 8.6 |
| SF-36 Mental Component Score (MCS) | 0.4 | 3.1 |
Related Topics and Keywords
ixekizumab, Lilly's Taltz, obesity, psoriatic arthritis, Zepbound™
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
